J
Joseph R. Arron
Researcher at Genentech
Publications - 129
Citations - 13277
Joseph R. Arron is an academic researcher from Genentech. The author has contributed to research in topics: Asthma & Lebrikizumab. The author has an hindex of 41, co-authored 117 publications receiving 11295 citations. Previous affiliations of Joseph R. Arron include University of Pennsylvania & Cornell University.
Papers
More filters
Journal ArticleDOI
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Prescott G. Woodruff,Barmak Modrek,David F. Choy,Guiquan Jia,Alexander R. Abbas,Almut Ellwanger,Joseph R. Arron,Laura L. Koth,John V. Fahy +8 more
TL;DR: Asthma can be divided into at least two distinct molecular phenotypes defined by degree of Th2 inflammation, and Th2 cytokines are likely to be a relevant therapeutic target in only a subset of patients with asthma.
Journal ArticleDOI
Lebrikizumab Treatment in Adults with Asthma
Jonathan Corren,Robert F. Lemanske,Nicola A. Hanania,Phillip E. Korenblat,Merdad V. Parsey,Joseph R. Arron,Jeffrey M. Harris,Heleen Scheerens,Lawren C. Wu,Zheng Su,Sofia Mosesova,Mark D. Eisner,Sean P. Bohen,John G. Matthews +13 more
TL;DR: Lebrikizumab treatment was associated with improved lung function and patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikIZumab than did patients with low periOSTin levels.
Journal ArticleDOI
TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells*
Brian Wong,Jaerang Rho,Joseph R. Arron,Elizabeth Robinson,Jason R. Orlinick,Moses V. Chao,Sergey Kalachikov,Eftihia Cayani,Frederick S. Bartlett,Wayne N. Frankel,Soo Young Lee,Yongwon Choi +11 more
TL;DR: A role for this TNF-related ligand in the regulation of the T cell-dependent immune response is suggested.
Journal ArticleDOI
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
Nicola A. Hanania,Sally E. Wenzel,Karin Rosén,Hsin-Ju Hsieh,Sofia Mosesova,David F. Choy,Preeti Lal,Joseph R. Arron,Jeffrey M. Harris,William W. Busse +9 more
TL;DR: The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups.
Journal ArticleDOI
Distinct molecular mechanism for initiating TRAF6 signalling.
Hong Ye,Joseph R. Arron,Joseph R. Arron,Betty Lamothe,Maurizio Cirilli,Takashi Kobayashi,Nirupama K. Shevde,Deena Segal,Oki K. Dzivenu,Masha Vologodskaia,Mijung Yim,Khoi Du,Sujay Singh,J. Wesley Pike,Bryant G. Darnay,Yongwon Choi,Hao Wu +16 more
TL;DR: Crystal structures of TRAF6 are reported to identify a universal mechanism by which TRAF 6 regulates several signalling cascades in adaptive immunity, innate immunity and bone homeostasis.